ACTH Treatment of APOL1- Associated Nephropathy
Last updated on April 2022Recruitment
- Recruitment Status
- Withdrawn
- Estimated Enrollment
- 30
Inclusion Criteria
- Strong clinical suspicion of APOL1-associated nephropathy or history of biopsy proven focal segmental glomerulosclerosis (FSGS) or focal global glomerulosclerosis (FGGS)
- BMI < 40 kg/m2
- Hemoglobin A1c <6.5%
- ...
- Strong clinical suspicion of APOL1-associated nephropathy or history of biopsy proven focal segmental glomerulosclerosis (FSGS) or focal global glomerulosclerosis (FGGS)
- BMI < 40 kg/m2
- Hemoglobin A1c <6.5%
- Age ≥21 years
- eGFR ≥30 ml/min/1.73m2
- Non-diabetic African-American with two APOL1-risk genotypes
- Women of childbearing potential: negative serum pregnancy test at Screening and agreement to follow a medically acceptable form of contraception for the duration of Acthar administration and 4 weeks thereafter
- Historical urine protein: creatinine ratio ≥ 1.0 g/g
Exclusion Criteria
- Unstable cardiovascular disease: history of congestive heart failure (NYHA Functional Class III-IV); history of dilated cardiomyopathy with ejection fraction < 40%; any of the following events within 3 months of screening: unstable angina, myocardial infarction, coronary artery bypass graft or percutaneous transluminal coronary angioplasty, transient ischemic attack or cerebrovascular accident, unstable arrhythmia
- Live or live attenuated vaccine received within 1 month prior to screening, or planned administration once enrolled in the study
- Contraindication to Acthar per package insert: scleroderma, osteoporosis, systemic fungal infections, ocular herpes simplex, recent surgery (within previous 6 months), history of or the presence of peptic ulcer (within 6 months prior to Screening), adrenal insufficiency or hyperfunction.
- ...
- Unstable cardiovascular disease: history of congestive heart failure (NYHA Functional Class III-IV); history of dilated cardiomyopathy with ejection fraction < 40%; any of the following events within 3 months of screening: unstable angina, myocardial infarction, coronary artery bypass graft or percutaneous transluminal coronary angioplasty, transient ischemic attack or cerebrovascular accident, unstable arrhythmia
- Live or live attenuated vaccine received within 1 month prior to screening, or planned administration once enrolled in the study
- Contraindication to Acthar per package insert: scleroderma, osteoporosis, systemic fungal infections, ocular herpes simplex, recent surgery (within previous 6 months), history of or the presence of peptic ulcer (within 6 months prior to Screening), adrenal insufficiency or hyperfunction.
- Diagnosis of diabetes mellitus and/or on pharmacologic treatment for diabetes
- Chronic systemic corticosteroid use (Prednisone or equivalent systemic steroid taken for more than 4 consecutive weeks within 6 months prior to screening). Intra-articular, inhaled, and topical steroids are not exclusion criteria.
- Biopsy proven glomerular disease other than FSGS or FGGS
- Current malignancy or history of malignancy within 5 years of screening, with the exception of non-melanoma skin cancers and cervical intraepithelial neoplasia
- Medical condition that could cause secondary FSGS
- Subject has a disorder that, in the opinion of the investigator, may compromise the ability of the subject to give written informed consent and/or comply with all required study procedures.
- Pregnant or breast feeding, or might become pregnant during the study or within 4 weeks after the end of treatment
- Uncontrolled hypertension (HTN) (≥ 180/110 mmHg) and frequent admissions (≥1 admission per 6 months interval) for hypertensive urgency or hypertensive emergency
- Acute glaucoma diagnosed ≤3 months prior to Screening
- History of any organ transplant
- History of secondary hypertension (i.e., renal artery stenosis, primary aldosteronism or pheochromocytoma)
- Known history of a primary immunodeficiency or an underlying condition such as splenectomy that predisposes the subject to infections
- Bipolar disorder, or Major Depressive Disorder characterized by severe depression requiring hospitalization, or history of suicidal ideation/attempts
- Subject is expected to initiate dialysis within 6 months
- Uncontrolled volume overload: history of moderate or severe peripheral edema; on loop diuretics ≥ 120 mg daily of furosemide or ≥ 3.0 mg daily of bumetanide or ≥ 150 mg daily of ethacrynic acid or ≥ 60 mg daily of torsemide;
- Currently enrolled in another interventional study, or less than 4 weeks since ending another interventional study(s) or receiving investigational agents(s)
- Treatment for any malignancy (e.g., radiation, chemotherapy, hormone therapy, or biologics) within 5 years of screening, with the exception of locally excised non-melanoma skin cancer or cervical intraepithelial neoplasia
- History of sensitivity to steroids (psychosis, steroid-induced diabetes)
- Known diagnosis of Human Immunodeficiency Virus, Hepatitis B, or Hepatitis C
- Previous treatment on a drug being investigated for the treatment of FSGS
- Systemic hematologic disease (e.g., hematologic malignancy, sickle cell anemia, myelodysplastic syndrome)
- Female of reproductive potential not willing to use highly effective methods of birth control during treatment and for 4 weeks after the end of treatment
- Currently receiving systemic antibiotics for treatment of an active infection; or history of frequent infections (more than one event per 6 months)
- Significant comorbidities (e.g., advanced malignancy, advanced liver disease) with a life expectancy of less than 1 year
Summary
- Conditions
- Kidney Disease
- Type
- Interventional
- Design
- Allocation: Non-Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
Participation Requirements
- Age
- Between 21 years and 125 years
- Gender
- Both males and females
Inclusion Criteria
- Strong clinical suspicion of APOL1-associated nephropathy or history of biopsy proven focal segmental glomerulosclerosis (FSGS) or focal global glomerulosclerosis (FGGS)
- BMI < 40 kg/m2
- Hemoglobin A1c <6.5%
- ...
- Strong clinical suspicion of APOL1-associated nephropathy or history of biopsy proven focal segmental glomerulosclerosis (FSGS) or focal global glomerulosclerosis (FGGS)
- BMI < 40 kg/m2
- Hemoglobin A1c <6.5%
- Age ≥21 years
- eGFR ≥30 ml/min/1.73m2
- Non-diabetic African-American with two APOL1-risk genotypes
- Women of childbearing potential: negative serum pregnancy test at Screening and agreement to follow a medically acceptable form of contraception for the duration of Acthar administration and 4 weeks thereafter
- Historical urine protein: creatinine ratio ≥ 1.0 g/g
Exclusion Criteria
- Unstable cardiovascular disease: history of congestive heart failure (NYHA Functional Class III-IV); history of dilated cardiomyopathy with ejection fraction < 40%; any of the following events within 3 months of screening: unstable angina, myocardial infarction, coronary artery bypass graft or percutaneous transluminal coronary angioplasty, transient ischemic attack or cerebrovascular accident, unstable arrhythmia
- Live or live attenuated vaccine received within 1 month prior to screening, or planned administration once enrolled in the study
- Contraindication to Acthar per package insert: scleroderma, osteoporosis, systemic fungal infections, ocular herpes simplex, recent surgery (within previous 6 months), history of or the presence of peptic ulcer (within 6 months prior to Screening), adrenal insufficiency or hyperfunction.
- ...
- Unstable cardiovascular disease: history of congestive heart failure (NYHA Functional Class III-IV); history of dilated cardiomyopathy with ejection fraction < 40%; any of the following events within 3 months of screening: unstable angina, myocardial infarction, coronary artery bypass graft or percutaneous transluminal coronary angioplasty, transient ischemic attack or cerebrovascular accident, unstable arrhythmia
- Live or live attenuated vaccine received within 1 month prior to screening, or planned administration once enrolled in the study
- Contraindication to Acthar per package insert: scleroderma, osteoporosis, systemic fungal infections, ocular herpes simplex, recent surgery (within previous 6 months), history of or the presence of peptic ulcer (within 6 months prior to Screening), adrenal insufficiency or hyperfunction.
- Diagnosis of diabetes mellitus and/or on pharmacologic treatment for diabetes
- Chronic systemic corticosteroid use (Prednisone or equivalent systemic steroid taken for more than 4 consecutive weeks within 6 months prior to screening). Intra-articular, inhaled, and topical steroids are not exclusion criteria.
- Biopsy proven glomerular disease other than FSGS or FGGS
- Current malignancy or history of malignancy within 5 years of screening, with the exception of non-melanoma skin cancers and cervical intraepithelial neoplasia
- Medical condition that could cause secondary FSGS
- Subject has a disorder that, in the opinion of the investigator, may compromise the ability of the subject to give written informed consent and/or comply with all required study procedures.
- Pregnant or breast feeding, or might become pregnant during the study or within 4 weeks after the end of treatment
- Uncontrolled hypertension (HTN) (≥ 180/110 mmHg) and frequent admissions (≥1 admission per 6 months interval) for hypertensive urgency or hypertensive emergency
- Acute glaucoma diagnosed ≤3 months prior to Screening
- History of any organ transplant
- History of secondary hypertension (i.e., renal artery stenosis, primary aldosteronism or pheochromocytoma)
- Known history of a primary immunodeficiency or an underlying condition such as splenectomy that predisposes the subject to infections
- Bipolar disorder, or Major Depressive Disorder characterized by severe depression requiring hospitalization, or history of suicidal ideation/attempts
- Subject is expected to initiate dialysis within 6 months
- Uncontrolled volume overload: history of moderate or severe peripheral edema; on loop diuretics ≥ 120 mg daily of furosemide or ≥ 3.0 mg daily of bumetanide or ≥ 150 mg daily of ethacrynic acid or ≥ 60 mg daily of torsemide;
- Currently enrolled in another interventional study, or less than 4 weeks since ending another interventional study(s) or receiving investigational agents(s)
- Treatment for any malignancy (e.g., radiation, chemotherapy, hormone therapy, or biologics) within 5 years of screening, with the exception of locally excised non-melanoma skin cancer or cervical intraepithelial neoplasia
- History of sensitivity to steroids (psychosis, steroid-induced diabetes)
- Known diagnosis of Human Immunodeficiency Virus, Hepatitis B, or Hepatitis C
- Previous treatment on a drug being investigated for the treatment of FSGS
- Systemic hematologic disease (e.g., hematologic malignancy, sickle cell anemia, myelodysplastic syndrome)
- Female of reproductive potential not willing to use highly effective methods of birth control during treatment and for 4 weeks after the end of treatment
- Currently receiving systemic antibiotics for treatment of an active infection; or history of frequent infections (more than one event per 6 months)
- Significant comorbidities (e.g., advanced malignancy, advanced liver disease) with a life expectancy of less than 1 year
Tracking Information
- NCT #
- NCT02006849
- Collaborators
- Not Provided
- Investigators
- Principal Investigator: Mariana Murea, MD Wake Forest University Health Sciences
- Mariana Murea, MD Wake Forest University Health Sciences